https://orcid.org/0000-0002-2589-8190
References
- Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
- Howlader N, Ries LA, Stinchcomb DG, et al. The impact of underreported veterans affairs data on national cancer statistics: analysis using population-based SEER Registries. J Natl Cancer Inst. 2009;101(7):533–536.
- Zhou H, Fu X, Li Q, et al. Safety and efficacy of anti-PD-1 monoclonal antibodies in patients with relapsed or refractory lymphoma: a meta-analysis of prospective clinic trails. Front Pharmacol. 2019;10:387.
- Bekoz H, Ozbalak M, Karadurmus N, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Hematol. 2020;99(11):2565–2576.
- Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129(10):1380–1388.
- Rivas MM, Berro M, Prates MV, et al. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transplant. 2020;55(1):117–125.
- Alpert AB, O'Dwyer KM. Allogeneic HSCT after PD-1 blockade: has post-transplant cyclophosphamide rendered checkpoint inhibition a safe bridge to allogeneic stem cell transplantation? Hematologist. 2020;17(4).
- Nieto JC, Roldán E, Jiménez I, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020;34(12):3420–3425.
- Re VD, Caggiari L, Repetto O, et al. Classical Hodgkin’s lymphoma in the era of immune checkpoint inhibition. J Clin Med. 2019;2019(8):1596.
- Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
- Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35(9):2672–2683.
- Manson G, Mear J-B, Herbaux C, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47–56.